Byotrol, the AIM listed anti-microbial technology company has secured a major contract to supply its technology to Irish based healthcare company Audit Diagnostics which will see Byotrol products used in healthcare laboratories worldwide.
The contract will see an initial order of £60,000 for Byotrol’s technology which is being incorporated into a range of antibacterial wipes, sprays and mousses.
These will be distributed to hospital and medical facilities worldwide under Audit Diagnostics’ Sterl STAT brand. The product range will be co-branded with Byotrol positioned as an ingredient brand in line with the company’s corporate brand development strategy.
The deal represents a significant milestone for Byotrol because hospital laboratories are among the most demanding environments from an infection control perspective with much of the knowledge and expertise on the subject concentrated within this area of a hospital or other medical establishment. The deal also means Byotrol’s technology will be deployed within hospitals on a global basis.
The company is confident that this is the first in a series of potential future orders from Audit Diagnostics and Byotrol’s technology offers a number of benefits over existing infection control methodologies.
Byotrol’s products have been proven through a programme of independent testing to be effective for up to seven days after application and work against a wide range of microorganisms including E. coli, Legionella and Listeria, as well as MRSA. The products are not toxic to humans and because of how the technology works, do not promote resistance in susceptible microorganisms. The chemicals used in the formulation of Byotrol products are suitable for use on a wide variety of surfaces and materials and do not damage or mark the materials during or after usage. They also present an extremely low toxicity profile to humans compared to other disinfectants in use within healthcare environments.
This news comes on the back of a recent announcement from Byotrol that it is seeking to extend its trial with a major NHS teaching hospital designed to test the efficacy of its products in combating the spread of hospital acquired MRSA. The initial phase of the trial was completed recently with encouraging preliminary results that show a significant reduction in environmental MRSA.
The company is now seeking to extend the scope of the trial to assess the effectiveness of Byotrol’s products across a wider range of operational clinical environments.
